Breaking Biotech

049 - Is Odonate's Hype Overblown?


Listen Later

Today, I talk breast cancer and how Odonate's oral Taxane (Tesataxel) could garner the attention of doctor's looking to alleviate the burden of IV chemotherapy infusion in their patients. I discuss the latest macro news, biotech news, and compare previous Taxane revenue to see if my model is reasonable. www.breakingbiotech.com biotech #breakingbiotech #odonate This is not investment advice, but for entertainment purposes. I am not liable for any losses you generate from trading. Support Breaking Biotech by donating to their Tip Jar: https://tips.pinecast.com/jar/breaking-biotech
...more
View all episodesView all episodes
Download on the App Store

Breaking BiotechBy Matthew Lepoire

  • 4.9
  • 4.9
  • 4.9
  • 4.9
  • 4.9

4.9

24 ratings